Drugs / FIDRISERTIB
FIDRISERTIB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03858075 | Feb → Sep 2019 | — | Blueprint Medicines Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05039515 | Dec 2021 → Mar 2026 | fibrodysplasia ossificans progressiva | Ipsen | Terminated | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FIDRISERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802133 ↗ |
| Known as | ALK2-IN-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802133 ↗ |
| Known as | BLU-782 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03858075 ↗ |
| Known as | BLU-782 sesquisuccinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802133 ↗ |
| Known as | FIDRISERTIB SUCCINATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802133 ↗ |
| Known as | IPN60130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05039515 ↗ |
| Modality | Small molecule | — CHEMBL4802133 ↗ |
| Route | Oral | “oral capsules” NCT03858075 ↗ |